Shares of Lantheus Holdings (LNTH) plummeted 5.03% in intraday trading on Tuesday following a significant downgrade from Truist Securities. The investment firm cut its rating on Lantheus from Buy to Hold and dramatically reduced its price target from $111 to $63, triggering a sell-off in the stock.
The downgrade comes as a substantial shift in Truist Securities' outlook for Lantheus, a company known for its diagnostic imaging agents and products. The sharp reduction in the price target, nearly halving the previous estimate, suggests that the analysts at Truist have reassessed their expectations for Lantheus' future performance and growth prospects.
Prior to this downgrade, Lantheus had maintained a generally positive outlook among analysts. According to FactSet data, the company had an average rating of "Buy" with a mean price target of $92. The stark contrast between Truist's new stance and the overall market sentiment underscores the potential impact of this downgrade on investor confidence, as reflected in today's significant stock price decline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.